ArticleBlood2021
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Abstract readLetter
In one paragraph
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Trial
- Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients.Blood cancer journal · 2022Trial
- Analysis of factors influencing SARS-CoV-2 infection and outcomes in patients with chronic lymphocytic leukemia during the burst of COVID-19 epidemic.BMC cancer · 2026Article
- State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.Blood cancer journal · 2025Article
- COVID-19 in patients with chronic lymphocytic leukemia treated with venetoclax: what is the role of anti-CD20 antibody?Blood advances · 2025Article
- Article
- COVID-19 vaccination during therapy in relation to COVID-19 death in CLL.Blood advances · 2024Article
- Article
- COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant.Cancers · 2024Article
- Management of infections for patient treated with ibrutinib in clinical practice.Frontiers in oncology · 2024Review
- COVID-19 in Patients with Chronic Lymphocytic Leukemia: What Have We Learned?Acta haematologica · 2024Review
- Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia.Acta haematologica · 2024Article
- Protracted course of SARS-CoV-2 pneumonia in moderately to severely immunocompromised patients.Clinical and experimental medicine · 2023Review
- T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.Molecular cancer therapeutics · 2023Article
- Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.Annals of hematology · 2023Article
- Coronavirus Disease-2019 in the Immunocompromised Host.Clinics in chest medicine · 2023Review
- Article
- Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.Blood advances · 2023Article
- COVID-19 in Adult Patients with Hematological Malignancies-Lessons Learned after Three Years of Pandemic.Biology · 2023Review
- B-cell malignancies and COVID-19: a narrative review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Review
Corrections and comments
- Commented on by
Authors and funding
52 authors.
Lindsey E RoekerMemorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3806-059X
Toby A EyreOxford University Hospitals, National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.ORCID 0000-0002-6631-9749
Meghan C ThompsonMemorial Sloan Kettering Cancer Center, New York, NY.
Nicole LamannaColumbia University Medical Center, New York, NY.
Alexander R ColtoffColumbia University Medical Center, New York, NY.
Matthew S DavidsDana-Farber Cancer Institute, Boston, MA.
Peter O BakerDana-Farber Cancer Institute, Boston, MA.
Lori LeslieJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
Kerry A RogersThe Ohio State University, Columbus, OH.ORCID 0000-0001-5748-7874
John N AllanNew York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-2088-0899
Raul CordobaFundacion Jimenez Diaz University Hospital, Madrid, Spain.ORCID 0000-0002-7654-8836
Alberto Lopez-GarciaFundacion Jimenez Diaz University Hospital, Madrid, Spain.ORCID 0000-0002-5354-5261
Darko AnticClinical Center Serbia, University of Belgrade, Belgrade, Serbia.
John M PagelSwedish Cancer Institute, Seattle, WA.
Nicolas Martinez-CalleNottingham University Hospitals, NHS Trust, Nottingham, United Kingdom.ORCID 0000-0002-5184-9464
José Antonio García-MarcoHospital Puerta de Hierro Majadahonda, Madrid, Spain.ORCID 0000-0002-8993-5982
Jose-Ángel Hernández-RivasHospital Infanta Leonor, Madrid, Spain.ORCID 0000-0003-4550-757X
Fatima MirasHospital Doce de Octubre, Madrid, Spain.ORCID 0000-0001-5096-3145
Catherine C CoombsThe University of North Carolina Cancer Center, Chapel Hill, NC.
Anders ÖsterborgKarolinska Institute, Solna, Sweden.
Lotta HanssonKarolinska Institute, Solna, Sweden.
Amanda N SeddonRush University Medical Center, Chicago, IL.
Javier López JiménezHospital Ramon y Cajal, Madrid, Spain.ORCID 0000-0002-2969-3002
Matthew R WilsonBeatson West of Scotland Cancer Centre, Glasgow, United Kingdom.ORCID 0000-0001-5423-3270
Dima El-SharkawiThe Royal Marsden Hospital, London, United Kingdom.ORCID 0000-0002-2752-5814
Daniel WojenskiRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Shuo MaRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Talha MunirSt James's University Hospital, Leeds, United Kingdom.
Susana ValencianoHospital Principe de Asturias, Alcala de Henares, Madrid, Spain.
Erlene SeymourKarmanos Cancer Institute, Wayne State University, Detroit, MI.
Paul M BarrUniversity of Rochester Wilmot Cancer Institute, Rochester, NY.ORCID 0000-0002-9733-401X
Jeffrey PuUpstate Cancer Center, Syracuse, NY.ORCID 0000-0001-7498-3159
Piers E M PattenComprehensive Cancer Centre, School of Cancer and Pharmaceutical Science, King's College London, United Kingdom.ORCID 0000-0003-3320-3034
Guilherme F PeriniHospital Israelita Albert Einstein, São Paulo, Brazil.
Scott F HuntingtonYale University, New Haven, CT.ORCID 0000-0001-7071-6475
Helen ParryMedical and Dental Sciences, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.ORCID 0000-0002-9707-8167
Suchitra SundaramRoswell Park Cancer Institute, Buffalo, NY.
Alan SkarbnikNovant Health, Charlotte, NC.
Manali KamdarUniversity of Colorado Cancer Center, Aurora, CO.
Ryan JacobsLevine Cancer Institute/Atrium Health, Charlotte, NC.
Harriet WalterLeicester Royal Infirmary, Leicester, United Kingdom.ORCID 0000-0003-2618-711X
Renata WalewskaRoyal Bournemouth Hospital, Bournemouth, United Kingdom.
Angus BroomWestern General Hospital, Edinburgh, United Kingdom.
Sonia LebowitzMemorial Sloan Kettering Cancer Center, New York, NY.
Krista M IsaacEmily Couric Clinical Cancer Center, Charlottesville, VA.ORCID 0000-0002-0234-139X
Craig A PortellEmily Couric Clinical Cancer Center, Charlottesville, VA.
Inhye E AhnNational Heart, Lung, and Blood Institute, Bethesda, MD.
Chaitra S UjjaniFred Hutchinson Cancer Research Center, Seattle, WA.
Mazyar ShadmanFred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-3365-6562
Sigrid S SkånlandDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University, Oslo, Norway; and.
Elise A ChongAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Anthony R MatoMemorial Sloan Kettering Cancer Center, New York, NY.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MMolecular Oncology Training ProgramT32CA203703 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Katherine D Crew, DAWN HERSHMAN · 2016 to 2026
$4.1MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA203703
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAntiviral AgentsCOVID-19Disease ManagementDrug Therapy, CombinationFemaleFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPrognosisRetrospective StudiesAntiviral Agents
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.